PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.

MLA

Liu, Qi, et al. “PARP-1 Inhibition with or without Ionizing Radiation Confers Reactive Oxygen Species-Mediated Cytotoxicity Preferentially to Cancer Cells with Mutant TP53.” Oncogene, vol. 37, no. 21, May 2018, pp. 2793–805. EBSCOhost, https://doi.org/10.1038/s41388-018-0130-6.

APA

Liu, Q., Gheorghiu, L., Drumm, M., Clayman, R., Eidelman, A., Wszolek, M. F., Olumi, A., Feldman, A., Wang, M., Marcar, L., Citrin, D. E., Wu, C.-L., Benes, C. H., Efstathiou, J. A., & Willers, H. (2018). PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene, 37(21), 2793–2805. https://doi.org/10.1038/s41388-018-0130-6

Chicago

Liu, Qi, Liliana Gheorghiu, Michael Drumm, Rebecca Clayman, Alec Eidelman, Matthew F Wszolek, Aria Olumi, et al. 2018. “PARP-1 Inhibition with or without Ionizing Radiation Confers Reactive Oxygen Species-Mediated Cytotoxicity Preferentially to Cancer Cells with Mutant TP53.” Oncogene 37 (21): 2793–2805. doi:10.1038/s41388-018-0130-6.